Home / Business and Economy / Humana Soars 15% on Stellar Medicare Ratings
Humana Soars 15% on Stellar Medicare Ratings
9 Oct
Summary
- Humana's 2027 Medicare Advantage plans received top ratings.
- Ratings improvement is expected to yield $4.8 billion in bonuses.
- Humana's performance outshines larger rivals like UnitedHealth and CVS.
Humana's shares experienced a notable 15% increase following analysts' acclaim for its leading position in the 2027 Medicare Advantage plan ratings. The health insurer revealed that 95% of its Medicare Advantage members will be part of plans rated four stars or higher for 2027, a substantial improvement from the 20% seen in 2026. This performance surpassed J.P. Morgan's projections.
This significant ratings boost is anticipated to bring substantial financial benefits, with estimates suggesting Humana could receive $4.8 billion in government bonus payments by 2028. Analysts attribute this turnaround to enhancements in drug-plan quality, health-plan quality, and readmission rates. The insurer had previously faced pressure due to a decline in its 2025 ratings, which impacted bonus payments.
Humana, a major provider of Medicare Advantage plans for individuals aged 65 and older and those with disabilities, now appears to be outperforming larger competitors like UnitedHealth and CVS Health in terms of their rated plan enrollments. The overall Medicare Advantage prescription drug plan landscape shows approximately 71% of enrollees in contracts projected to receive four-star or higher ratings for 2027.
